Skip to Content
Morningstar

Centene Corp CNC Stock Quote

Morningstar Rating
| Rating as of

NYSE:CNC

Morningstar‘s Stock Analysis CNC

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Centene Delivers Strong Q3 and Gives Solid Intermediate-Term Profit Goals; No FVE Change

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Centene turned in solid third-quarter results, including strong performance in its key end markets—Medicaid (low-income Americans) and Medicare Advantage (older Americans)—which allowed management to slightly increase the bottom end of its 2022 EPS outlook. Also, on the call, management gave a preview of its 2023 and 2024 profit goals, which are roughly in line with our estimates. Considering that solid outlook, we are maintaining our $95 fair value estimate.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CNC

More

Company Profile CNC

Business Description

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 23 million medical members as of September 2022, mostly in Medicaid (70% of membership), the individual exchanges (9%), Medicare Advantage (7%), and the balance in Tricare (West region), correctional facility, and commercial plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Contact
7700 Forsyth Boulevard, Centene Plaza
St. Louis, MO, 63105
T +1 314 725-4477
Sector Healthcare
Industry Healthcare Plans
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 72,500

Related News CNC

Stock Strategist Industry Reports

Healthcare Policy Changes Could Result in Opportunities

Expanded insurance rolls would be good news for the managed-care organizations and service providers we cover.
Julie Utterback
Stock Analyst Update

Supreme Court Ruling to Uphold ACA

This decision adds certainty to related health insurance programs.
Julie Utterback
Market Update

The Winners of the New Definition of Infrastructure

Depending on which broader infrastructure projects take shape, numerous companies could see increased demand.
David Sekera
Our Picks

11 Undervalued Climate-Friendly Stocks

These companies are well-positioned for a world less dependent on fossil fuels.
Susan Dziubinski
Stock Strategist Industry Reports

What a Democratic Sweep Means for Healthcare

We think the insurers could be most influenced by potential reforms.
Julie Utterback
Stock Strategist Industry Reports

Election Impact on U.S. Healthcare Looks Modest

Our moat ratings and undervalued view of the MCO and drug/biotech sectors are intact.
Julie Utterback
Commentary

Key ESG Issues Up for Shareholder Vote

Employee welfare and political influence are among the big environmental, social, and governance issues this year.
Jackie Cook
Our Picks

10 Undervalued Stocks With Momentum

These quality stocks have gained more than 15% in the last three months yet still look undervalued to us.
Susan Dziubinski
Stock Strategist Industry Reports

Investing With Our 2020 Healthcare Policy Outlook

We see risks for managed care but also opportunities to own moatworthy companies at sizable discounts.
Jake Strole
Credit Insights

New Issue Corporate Bond Market Reaches a Frenzied Pace

The draw of low interest rates combined with tight credit spreads keeps issuers coming back to the market for more.
David Sekera
Quarter-End Insights

Our Outlook for Health-Care Stocks

With macro-conditions improving, the focus should return to fundamentals in health care.
Alex Morozov
US Videos

Did Health-Care Reform Die in Massachusetts?

Health-care analyst Matt Coffina thinks the odds for health-care reform passing are around 50%, but that either way the impact on industry will be muted.
Pat Dorsey